Compare NGL & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NGL | OMER |
|---|---|---|
| Founded | 1940 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 751.7M | 894.8M |
| IPO Year | 2011 | 2009 |
| Metric | NGL | OMER |
|---|---|---|
| Price | $12.09 | $11.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 505.4K | ★ 2.4M |
| Earning Date | 02-03-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $1,161,150,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $355.35 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.64 | $2.95 |
| 52 Week High | $13.00 | $17.65 |
| Indicator | NGL | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 71.60 | 44.44 |
| Support Level | $10.11 | $11.44 |
| Resistance Level | $13.00 | $12.18 |
| Average True Range (ATR) | 0.65 | 0.66 |
| MACD | 0.18 | -0.19 |
| Stochastic Oscillator | 75.36 | 6.75 |
NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, as well as for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.